Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide.
Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents …

Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized
patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A …

Multidrug-resistant Acinetobacter baumannii is recognized to be among the most difficult
antimicrobial-resistant gram-negative bacilli to control and treat. Increasing antimicrobial …

Carbapenem-resistant Acinetobacter baumannii (CRAB) causes colonization and infection
predominantly in hospitalized patients. Distinction between the two is a challenge. When …

The first decade of the 20th century witnessed a surge in the incidence of infections due to
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …

Carbapenems are considered the treatment of choice for Acinetobacter baumannii
infections. Many facilities implement preventive measures toward only carbapenem-resistant …

Introduction: Although the clinical importance of Acinetobacter pittii and Acinetobacter
nosocomialis has increased in the nosocomial setting in the last decade, infections caused …

Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases Log in or …

The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not
been established. Carbapenems are the mainstay of treatment in susceptible isolates …

Amid the recent attention focused on the growing impact of methicillin-resistant
Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa infections, the …